| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 250K | 0 | 3.15M |
| COGS % of Revenue | - | - | - |
| Gross Profit | -250K | 0 | -3.15M |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | 1% | - |
| Operating Expenses | 113.6M | 158.17M | 297.6M |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 12.55M | 20.5M | 35.2M |
| SG&A % of Revenue | - | - | - |
| Research & Development | 101.05M | 137.68M | 265.55M |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 0 | 0 | -3.15M |
| Operating Income | -113.85M | -158.17M | -300.75M |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -0.39% | -0.9% |
| EBITDA | -113.6M | -156.89M | -297.6M |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | -0.38% | -0.9% |
| D&A (Non-Cash Add-back) | 250K | 1.28M | 3.15M |
| EBIT | -113.85M | -158.17M | -300.75M |
| Net Interest Income | 1.99M | 3.37M | 12.02M |
| Interest Income | 1.99M | 3.37M | 12.02M |
| Interest Expense | 0 | 0 | 0 |
| Other Income/Expense | 1.92M | 3.18M | 6.52M |
| Pretax Income | -111.93M | -154.99M | -294.23M |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% |
| Net Income | -111.93M | -154.99M | -294.23M |
| Net Margin % | - | - | - |
| Net Income Growth % | - | -0.38% | -0.9% |
| Net Income (Continuing) | -111.93M | -154.99M | -294.23M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -14.93 | -2.99 | -10.38 |
| EPS Growth % | - | 0.8% | -2.47% |
| EPS (Basic) | -14.93 | -2.99 | -10.38 |
| Diluted Shares Outstanding | 7.5M | 51.84M | 28.34M |
| Basic Shares Outstanding | 7.5M | 51.84M | 28.34M |
| Dividend Payout Ratio | - | - | - |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 102.56M | 53.36M | 306.19M |
| Cash & Short-Term Investments | 92.86M | 48.95M | 288.26M |
| Cash Only | 25.61M | 46M | 169.53M |
| Short-Term Investments | 67.25M | 2.96M | 118.74M |
| Accounts Receivable | 500K | 722K | 1.81M |
| Days Sales Outstanding | - | - | - |
| Inventory | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 206K | 208K | 762K |
| Total Non-Current Assets | 5.61M | 36.26M | 34.8M |
| Property, Plant & Equipment | 4.47M | 35.22M | 33.69M |
| Fixed Asset Turnover | - | - | - |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 1.14M | 1.03M | 1.11M |
| Total Assets | 108.17M | 89.61M | 340.99M |
| Asset Turnover | - | - | - |
| Asset Growth % | - | -0.17% | 2.81% |
| Total Current Liabilities | 13.35M | 20.87M | 50.91M |
| Accounts Payable | 1.72M | 1.12M | 9.62M |
| Days Payables Outstanding | 2.51K | - | 1.11K |
| Short-Term Debt | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 |
| Other Current Liabilities | 3.58M | 5.58M | 7.76M |
| Current Ratio | 7.68x | 2.56x | 6.01x |
| Quick Ratio | 7.68x | 2.56x | 6.01x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 290.06M | 408M | 29.98M |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 469K | 30.86M | 29.16M |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 289.59M | 377.14M | 814K |
| Total Liabilities | 303.41M | 428.87M | 80.89M |
| Total Debt | 1.78M | 32.58M | 30.72M |
| Net Debt | -23.83M | -13.42M | -138.8M |
| Debt / Equity | - | - | 0.12x |
| Debt / EBITDA | - | - | - |
| Net Debt / EBITDA | - | - | - |
| Interest Coverage | - | - | - |
| Total Equity | -195.24M | -339.26M | 260.1M |
| Equity Growth % | - | -0.74% | 1.77% |
| Book Value per Share | -26.04 | -6.54 | 9.18 |
| Total Shareholders' Equity | -195.24M | -339.26M | 260.1M |
| Common Stock | 1K | 1K | 4K |
| Retained Earnings | -209.32M | -364.32M | -658.55M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | -127K | 2K | 40K |
| Minority Interest | 0 | 0 | 0 |
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -107.72M | -129.97M | -255.08M |
| Operating CF Margin % | - | - | - |
| Operating CF Growth % | - | -0.21% | -0.96% |
| Net Income | -111.93M | -154.99M | -294.23M |
| Depreciation & Amortization | 250K | 1.28M | 3.15M |
| Stock-Based Compensation | 5.96M | 8.63M | 19.46M |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | -86K | 3.05M | 1.79M |
| Working Capital Changes | -1.92M | 12.06M | 14.76M |
| Change in Receivables | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 1.29M | -642K | 8.51M |
| Cash from Investing | -68.75M | 60.47M | -113.79M |
| Capital Expenditures | -2.41M | -4.5M | -1.73M |
| CapEx % of Revenue | - | - | - |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | 0 | 0 | 0 |
| Cash from Financing | 101.63M | 89.68M | 492.37M |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | 1.73M | -96K | 40.59M |
| Net Change in Cash | - | - | - |
| Free Cash Flow | -110.13M | -134.47M | -256.81M |
| FCF Margin % | - | - | - |
| FCF Growth % | - | -0.22% | -0.91% |
| FCF per Share | -14.69 | -2.59 | -9.06 |
| FCF Conversion (FCF/Net Income) | 0.96x | 0.84x | 0.87x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Return on Equity (ROE) | - | - | -113.12% |
| Debt / Equity | - | - | 0.12x |
| FCF Conversion | 0.96x | 0.84x | 0.87x |
Alumis Inc. Common Stock (ALMS) reported $22.1M in revenue for fiscal year 2024.
Alumis Inc. Common Stock (ALMS) grew revenue by 0.0% over the past year. Growth has been modest.
Alumis Inc. Common Stock (ALMS) reported a net loss of $245.2M for fiscal year 2024.
Alumis Inc. Common Stock (ALMS) has a return on equity (ROE) of -113.1%. Negative ROE indicates the company is unprofitable.
Alumis Inc. Common Stock (ALMS) had negative free cash flow of $373.4M in fiscal year 2024, likely due to heavy capital investments.